ACH
IOVA icon

ArrowMark Colorado Holdings’s Iovance Biotherapeutics IOVA Stock Holding History

ArrowMark Colorado Holdings’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-77,863
Closed -$2.56M – 344
2020
Q3 		$2.56M Hold
77,863
– – 0.02% 247
2020
Q2 		$2.14M Hold
77,863
– – 0.02% 228
2020
Q1 		$2.33M Hold
77,863
– – 0.03% 211
2019
Q4 		$2.15M Hold
77,863
– – 0.02% 242
2019
Q3 		$1.42M Hold
77,863
– – 0.01% 235
2019
Q2 		$1.91M Buy
+77,863
New +$1.17M 0.02% 247

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ArrowMark Colorado Holdings's IOVA Position: Q4 2020 in Review

ArrowMark Colorado Holdings sold out of Iovance Biotherapeutics (IOVA) in Q4 2020, closing a stake of 77,863 shares — an estimated $2.56M sold.

ArrowMark Colorado Holdings first reported a position in IOVA in Q2 2019 and held it in 6 quarters. The position peaked at $2.56M in Q3 2020. 269 funds tracked by Wall St. Rank hold IOVA as of Q4 2020.

  • ArrowMark Colorado Holdings reported no remaining Iovance Biotherapeutics position as of Q4 2020 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 77,863 Iovance Biotherapeutics shares in Q4 2020, an estimated $2.56M.
  • ArrowMark Colorado Holdings first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 6 quarters.
  • ArrowMark Colorado Holdings's Iovance Biotherapeutics position peaked at $2.56M in Q3 2020.
  • 269 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2020.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2020, filed 16 Feb 2021.